|
| Press Releases |
|
 |
|
| Wednesday, April 14, 2021 |
|
|
エーザイ、米国神経学会年次総会にて神経領域の開発品・製品に関する最新データを発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2021年4月17日から22日までバーチャルで開催される「米国神経学会（American Academy of Neurology）年次総会：AAN2021」において、抗アミロイドB（AB）プロトフィブリル抗体lecanemab（開発品コード：BAN2401）、デュアルオレキシン受容体拮抗剤レンボレキサント（製品名「デエビゴ(R)」、海外製品名「Dayvigo(R)」）および抗てんかん剤ペランパネル（製品名「フィコンパ(R)」、海外製品名「Fycompa(R)」）に関する最新データを発表しますのでお知らせします。 more info >> |
|
| Monday, April 12, 2021 |
|
|
エーザイ、リンパ系フィラリア症の制圧活動に関するアニメーション動画がInternational Society for Neglected Tropical Diseasesフェスティバルアワード2021で「アニメーション賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、リンパ系フィラリア症（LF）の制圧活動をテーマとして当社が制作したアニメーション動画「Leave No One Behind―顧みられない人々の病気―」が、International Society for Neglected Tropical Diseases （ISNTD）フェスティバルアワード 2021 の「アニメーション賞」を受賞したことをお知らせします。 more info >> |
|
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
| Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
| Wednesday, March 31, 2021 |
|
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
| KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
| Tuesday, March 30, 2021 |
|
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
| Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
|
エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩（製品名：「レンビマ(R)」、「Kisplyx(R)」、以下 レンバチニブ）について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.（北米以外ではMSD）の抗PD-1抗体ペムブロリズマブ（製品名：「キイトルーダ(R)」、以下 ペムブロリズマブ）との併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る適応追加の申請をそれぞれ行い、欧州医薬品庁によって受理されましたのでお知らせします。 more info >> |
|
| Friday, March 26, 2021 |
|
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
| Tuesday, March 23, 2021 |
|
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
|
エーザイとMSD、「レンビマ(R)」（レンバチニブ）について日本において「切除不能な胸腺癌」の効能効果の承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とMerck & Co., Inc., Kenilworth, N.J., U.S.A.の日本法人であるMSD株式会社（本社：東京都千代田区、代表取締役社長： カイル・タトル、以下 MSD）は、本日、エーザイ創製のマルチキナーゼ阻害剤「レンビマ(R)」（一般名：レンバチニブメシル酸塩）について、日本において「切除不能な胸腺癌」の効能効果追加の承認を取得したことをお知らせします。本剤は、日本における「切除不能な胸腺癌」に対する初めての承認薬剤となります。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kaplan Fox & Kilsheimer LLP is Investigating DexCom, Inc. (DXCM) for Potential Securities Law Violations
Jul 27, 2024 18:00 HKT/SGT
|
|
|
SMG Deadline to Lead in Securities Fraud Lawsuit is August 5, 2024 - Contact Kaplan Fox & Kilsheimer LLP
Jul 27, 2024 18:00 HKT/SGT
|
|
|
Funimation Founder, Gen Fukunaga, Joins as Investor and Advisor to Toonsutra, India's #1 Webtoon App
Jul 27, 2024 17:00 HKT/SGT
|
|
|
Domino's Pizza Inc. Is Being Investigated by Kaplan Fox & Kilsheimer LLP for Potential Securities Law Violations
Jul 26, 2024 23:30 HKT/SGT
|
|
|
VCI Global Enters into AI Computing Alliance (AICA) Led by Enlight Corporation and Supermicro
Jul 26, 2024 21:00: JST
|
|
|
CORRECTION FROM SOURCE: Doubleview Reports Maiden Mineral Resource Estimate
Jul 26, 2024 21:00 HKT/SGT
|
|
|
CITIC Resources Announces its 2024 Interim Results
Jul 26, 2024 20:43 HKT/SGT
|
|
|
中信資源公布2024年度中期業績 收入大幅增長93.1%至約39.4億港元
Jul 26, 2024 20:29 HKT/SGT
|
|
|
OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology
Jul 26, 2024 20:05 HKT/SGT
|
|
|
VCI Global Enters into AI Computing Alliance (AICA) Led by Enlight Corporation and Supermicro
Jul 26, 2024 20:00 HKT/SGT
|
|
|
中信资源公布2024年度中期业绩 收入大幅增长93.1%至约39.4亿港元
Jul 26, 2024 19:57 HKT/SGT
|
|
|
華邦科技集團成員及策略夥伴攬獲「專業金融機構服務大獎2024」兩項殊榮 [更新版]
Jul 26, 2024 17:42 HKT/SGT
|
|
|
华邦科技集团成员及策略伙伴揽获“专业金融机构服务大奖2024”两项殊荣[更新版]
Jul 26, 2024 17:18 HKT/SGT
|
|
|
DOCOMO and NTT Com Jointly Demonstrate Practicality of DOCOMO's New Multi-platform Cloud-rendering Technology
Jul 26, 2024 17:05 JST
|
|
|
Kucingko Berhad Debuts on ACE Market with Clawsome Opening Price of RM0.805
Jul 26, 2024 15:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
